EyePoint (EYPT)

[winston]

not vested

EyePoint: DURAVYU's Durability Could Drive Significant Upside

EyePoint is rated a clear BUY, with central-case DCF modeling indicating roughly 2x upside from current levels.

DURAVYU, EYPT's lead candidate for wet AMD and DME, has demonstrated a compelling durability profile in Phase 2 and could benefit from a large, high-turnover wet AMD market if confirmed.

Probability-adjusted DCF values DURAVYU at ~$2.9B pre-dilution, with a final equity value of ~$2.3B and ~$27/share after an estimated 20% dilution.

Key risks include a ~39% chance of Phase 3 failure, regulatory complexities as a drug-device, and commercial adoption uncertainty amid evolving competition.

Source: Seeking Alpha

https://seekingalpha.com/article/490436 ... ant-upside